- Home
- ABVC
ABVC
ABVC BioPharma Inc.
as 07-26-2024 4:00pm EST
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 9.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 122.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.67 - $5.08 | Next Earning Date: | 08-12-2024 |
| Revenue: | $25,363 | Revenue Growth: | -97.63% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ABVC BioPharma Inc. News
ABVC Breaking Stock News: Dive into ABVC Ticker-Specific Updates for Smart Investing
NewMediaWire
18 days ago
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
NewMediaWire
24 days ago
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
NewMediaWire
a month ago
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
NewMediaWire
a month ago
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
NewMediaWire
2 months ago
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
NewMediaWire
2 months ago
ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M
NewMediaWire
2 months ago
Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M
NewMediaWire
3 months ago
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Compare ABVC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABVC ABVC BioPharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.